Inhibikase Therapeutics EBIT

As of the most recent data (March 2026), IKT shows a EBIT of $-55M. That compares with $-40M in the prior-year period — down 37.8% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IKT's EBIT is now $-55M (was $-40M) — a 37.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Inhibikase Therapeutics is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. Inhibikase Therapeutics is at $-55M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how IKT stacks up against individual peers as well.

Tracking IKT's ebit over time shows whether Inhibikase Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-55M That compares with $-40M in the prior-year period — down 37.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Inhibikase Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-55M) with ownership activity and broader fundamentals.